Zerigo Health Announces Release of Eczema Solution

•Zerigo Health’s latest software release includes integrated, guideline-recommended phototherapy dosing protocols for the treatment of atopic dermatitis (commonly referred to as eczema), in addition to its existing protocols for psoriasis

•Evernorth, Cigna’s health services business, will offer Zerigo’s solution as part of a pilot program through its Digital Health Formulary and is the first to launch this new platform for both psoriasis and eczema

San Diego, CA – Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, today announced the launch of a new software release which includes integration of the American Academy of Dermatology Guideline protocols for the treatment of eczema with narrowband ultraviolet B (NB-UVB) phototherapy.

Evernorth, Cigna Corporation's health services business, is the first to launch Zerigo's solution for both psoriasis and eczema, which will be offered as a pilot program through its Digital Health Formulary. The Evernorth Digital Health Formulary connects employers, insurers and patients with innovative, affordable, and evidence-based care that meets their broader health care needs. The pilot program will enable more people with chronic skin conditions to better manage their conditions.

Click here for the rest of the press release shared on Zerigo’s website or a PDF copy of the file here.

Shared by Drew Doshier, board observer of Zerigo Health.